[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

DMARDs Not Linked to Alzheimer Risk for Seniors With RA
TUESDAY, April 12, 2022 -- For patients with rheumatoid arthritis aged 65 years and older, the risk of Alzheimer disease and related dementia (ADRD) does not differ with tofacitinib, tocilizumab, or tumor necrosis factor (TNF) inhibitors compared... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche's Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and has granted Priority Review for Actemra®/RoActemra® (tocilizumab) intravenous for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. (Source: World Pharma News)
Source: World Pharma News - April 4, 2022 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Common COVID Drug, Tocilizumab (Actemra), Might Be Useful at Lower Dose
THURSDAY, March 24, 2022 -- A lower dose of a widely used COVID-19 drug is just as effective as a higher dose, new research shows. Tocilizumab (Actemra) is a rheumatoid arthritis drug that has become the standard of care for treating severe... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 24, 2022 Category: General Medicine Source Type: news

Lower dose of COVID-19 drug is effective — and allows treatment for more
Responding to a shortage of tocilizumab, an important treatment for severe COVID-19, a new study finds a lower dose is effective and extends treatment options. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 23, 2022 Category: Universities & Medical Training Source Type: news

What's the Evidence Base for Prescribing New SSc-ILD Drugs? What's the Evidence Base for Prescribing New SSc-ILD Drugs?
Two experts from Hospital for Special Surgery review the evidence for how best to use nintedanib, tocilizumab, and combination therapy in treating patients with systemic sclerosis –associated ILD.Hospital for Special Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2022 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

RECOVERY Trial shows baricitinib reduces deaths in COVID-19 hospitalised patients, NIHR
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth. The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2022 Category: Consumer Health News Source Type: news

Analysis Questions Tocilizumab in Ventilated COVID Patients Analysis Questions Tocilizumab in Ventilated COVID Patients
Statistical review of earlier meta-analysis supports use of arthritis drug in hospitalized patients on noninvasive respirationMedscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - March 3, 2022 Category: Emergency Medicine Tags: Critical Care News Source Type: news

U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Media News - February 22, 2022 Category: Pharmaceuticals Source Type: news

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. (Source: World Pharma News)
Source: World Pharma News - February 14, 2022 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemi c corticosteroids and require supplemental oxygen or mechanical ventilation.1 It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health. (Source: Roche Investor Update)
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news